Protalix BioTherapeutics (PLX) Stock Soars On Data

Protalix Biotherapeutics PLX Stock News

The Market Potential Here Is Compelling

Protalix could be working its way into a very large market. The clinical study this data came from is a Phase 3 study. Considering that the data continues to be this positive, there’s a strong chance that the drug will be approved by the FDA.

Should the drug be approved by the FDA, PLX will be embarking on a very large opportunity. In fact, experts believe that the Fabry disease market will grow to be worth $3.12 billion annually by the year 2025.

While it would be pretty foolish to suggest that a single company would take 100% of or even the vast majority of a large market like this, PLX doesn’t need to. Trading with a market cap of under $50 million, if the company were to access even a small portion of the Fabry disease market, it would earn multiples of its market cap in revenue annually.

Considering the size of the company and the size of the market it could be embarking on, this is an opportunity that’s hard to ignore.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Continue Reading

Click below to continue reading!

Pages: 1 2 3 4

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.